Behavioral effects of CCK(B) receptor ligands in a validated simulation of panic anxiety in rats

European Neuropsychopharmacology

Volumn 6, Issue 4, 1996, Pages 291-298

  Jenck, François ^a   Martin, James R ^a   Moreau, Jean Luc ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

animal model; anxiety; brain stimulation; CCK; panic

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ALPRAZOLAM; CAFFEINE; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ DERIVATIVE; CLONAZEPAM; YOHIMBINE; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; INDOLE DERIVATIVE; MEGLUMINE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BRAIN DEPTH STIMULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PANIC; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; ANIMAL; DOSE RESPONSE; WISTAR RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BENZODIAZEPINONES; CAFFEINE; CLONAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; MALE; MEGLUMINE; PHENYLUREA COMPOUNDS; RATS; RATS, WISTAR;

EID: 0030273897     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(96)00033-8     Document Type: Article

References (40)

1. Boden, P.R. and Woodruff, G.N. (1994) Benzodiazepine/cholecystokinin interactions at functional CCK receptors in rat brain. Br. J. Pharmacol. 112, 429-434.
2. Bourin, M. (1995) Provocation of panic as a tool for investigating the disorder. Eur. Neuropsychopharmacol. 5 (Suppl.), 183.
3. Bradwejn, J., Koszycki, D. and Bourin, M. (1991a) Dose ranging study of the effects of cholecystokinin in healthy volunteers. J. Psychiatry Neurosci. 16, 260-264.
4. Bradwejn, J., Koszycki, D. and Shriqui, C. (1991b) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch. Gen. Psychiatry 48, 603-610.
5. Bradwejn, J., Koszycki, D., Payeur, R., Bourin, M. and Borthwick, H. (1992) Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am. J. Psychiatry 149, 962-964.
6. Bradwejn, J., Koszycki, D., Couetoux duTertre, A., Van Megen, H., Den Boer, J., Westenberg, H., and Annable, L. (1994) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch. Gen. Psychiatry 51, 486-493.
7. Bradwejn, J., Koszycki, D., Paradis, M., Reece, P., Hinton, J. and Sedman, A. (1995) Effect of CI-988 on cholecystokinin tetrapetide-induced panic symptoms in healthy volunteers. Biol. Psychiatry 38, 742-746.
8. Brodin, K., Ogren, S.O. and Brodin, E. (1994) Clomipramine and clonazepam increase cholecystokinin levels in rat ventral tegmental area and limbic regions. Eur. J. Pharmacol. 263, 175-180.
9. Charrier, D., Dangoumau, L., Puech, A., Hamon, M. and Thiébot, M.H. (1995) Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology 121, 127-134.
10. Chopin, P. and Briley, M. (1993) The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology 110, 409-414.
11. B receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology 121, 109-117.
12. Delgado, J.M., Robert, W. and Miller, N.E. (1954) Learning motivated by electrical stimulation of the brain stem. Am. J. Physiol. 179, 587-593.
13. De Montigny, C. (1989) Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch. Gen. Psychiatry 46, 511-517.
14. B receptors involved in animal models of anxiety. Pharmacol. Biochem. Behav. 49, 133-141.
15. B receptor antagonist CI-988 and diazepam in the four-plate test. Psychopharmacology 112, 452-454.
16. Fekete, M., Lengyel, A., Hegedus, B., Penke, B., Zarandy, M., Toth, G.K. and Teleddy, G. (1984) Further analysis of the effects of cholecystokinin octapeptides on avoidance behaviour in rats. Eur. J. Pharmacol. 98, 79-91.
17. Feng, R., Hinton, J.P., Hoffmann, K.L., Parker III, T.D. and Wright, D.S. (1993) Pharmacokinetics and oral bioavailability of CI-988 ester prodrugs in Wistar rats. Pharm. Res. 10, Abstr. PPDM 8189.
18. Harro, J. and Vasar, E. (1991) Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behavior? Neurosci. Biobehav. Rev. 15, 473-477.
19. Harro, J.,Vasar, E. and Bradwejn, J. (1993) CCK in animal and human research on anxiety. Trends Pharmacol. Sci. 14, 224-249.
20. Hughes, J., Boden, P., Costall, B., Domeney, A., Kelly, E., Horwell D., Hunter, J.C., Pinnock, R.D., and Woodruff, G.N. (1990) Development of a class of selective cholecystokinm type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA 87, 6728-6732.
21. Innis, R.B. and Snyder, S.H. (1980) Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. USA 77, 6917-1919.
22. Jenck, F., Broekkamp, C.L.E. and Van Delft, A.M.L. (1990) The effects of antidepressants on aversive periaqueductal stimulation in rats. Eur. J. Pharmacol. 177, 201-204.
23. Jenck, F., Moreau, J.L. and Martin, J.R. (1995) Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res. 57, 181-191.
24. Johnson, M.R., Lydiard, R.B. and Ballenger, J.C. (1995) Panic disorder: pathophysiology and drug treatment. Drugs 49, 328-344.
25. B antagonist, in panic disorder. Biol. Psychiatry 37, 462-466.
26. B) ligand: L-365,260. Eur. J. Pharmacol. 162, 273-280.
27. B/gastrin receptor antagonists. Drugs Future 18, 919-931.
28. Mongeau, R. and Marsden, C.A. (1995) Effect of CCK4 administration on panic-like reactions produced by stimulation of the dorsal periacqueductal grey area in the rat. Br. J. Pharmacol. 116 (Suppl.), 351 p.
29. Nashold, B.S., Wilson, W.P. and Slaughter, D.G. (1969) Sensations evoked by stimulation of the midbrain of man. J. Neurosurg. 30, 14-24.
30. B receptor antagonists by ex vivo binding. Eur. J. Pharmacol. 253, 237-244.
31. Paxinos, G. and Watson, C. The Rat Brain in Stereotaxic Coordinates. Academic Press, New York, 1982.
32. Pisegna, J.R., De Weerth, A., Huppi, K. and Wank, S.A. (1992) Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization. Biochem. Biophys. Res. Commun. 189, 296-301.
33. B antagonist, on the punished responding of squirrel monkeys. Neuropeptides 19 (Suppl.): 75-78.
34. Ravard, S. and Dourish, C.T. (1990) Cholecystokinin and anxiety. Trends Pharmacol. Sci. 11, 271-273,
35. Schmitt, P., Sandner, G., and Karli, P. (1981) Escape and approach induced by brain stimulation: a parametric analysis. Behav. Brain Res. 2, 49-79.
36. Schmitt, P., Di Scala, G., Jenck, F., and Sandner, G. (1984) Periventricular structures, elaboration of aversive effects and processing of sensory information. In: Modulation of Sensorimotor Activity during Alterations in Behavioral States. Alan R. Liss, Inc., New York, pp. 393-414.
37. Singh, L., Field, M.J., Hughes, J., Menzies, R., Oles, R.J., Vass, C.A. and Woodruff, G.N. (1991) The behavioral properties of CI-988, a selective cholecystokinin B receptor antagonist. Br. J. Pharmacol. 104, 239-245.
38. Swiss Academy of Sciences and Swiss Academy of Medical Sciences (1995) Ethical principles and guidelines for experiments on animals. Experientia 51, 1-3.
39. Westenberg, H.G.M. and Den Boer, J.A. (1993) New findings in the treatment of panic disorder. Pharmacopsychiatry 26, 30-33.
40. Wettstein, J.G., Buéno, L. and Junien, J.L. (1994) CCK antagonists: pharmacology and therapeutic interest. Pharmacol. Ther. 62, 267-282.